QSC RESEARCH GRADE
≥99% HPLC PurityMS ConfirmedJanoshik COAIn-House SPPS5-Region Domestic Shipping
What is Eloralintide?
Eloralintide (MEDI0382 / cotadutide) is a 31-amino acid dual GLP-1R/GCGR co-agonist developed by AstraZeneca/MedImmune. It simultaneously activates the GLP-1 receptor (appetite suppression, insulin secretion, gastric emptying) and the glucagon receptor (GCGR — hepatic CPT1A upregulation driving direct fatty acid β-oxidation, UCP1-mediated thermogenesis, energy expenditure increase). Phase 2b: ~10–11% weight reduction at 26 weeks. Phase 2 NASH: ~40–50% liver fat reduction (MRI-PDFF) — direct GCGR mechanism independent of body weight loss. The leading dual GLP-1R/GCGR research tool for NASH/MAFLD and hepatic lipid metabolism biology.
Research Applications
Dual GLP-1R/GCGR Pharmacology
GCGR/CPT1A hepatic fat oxidation mechanism; GLP-1R+GCGR co-agonism vs GLP-1R-only reference compounds
NASH / MAFLD Research
Phase 2: ~40–50% liver fat ↓ (MRI-PDFF), ALT normalisation, NASH histology improvement — direct hepatic mechanism
Weight Loss Biology
Phase 2b: ~10–11% weight reduction at 26 weeks; UCP1/BAT thermogenesis via GCGR
Hepatic Lipid Metabolism
CPT1A upregulation, mitochondrial β-oxidation, hepatic glucose production reduction, VLDL/TG biology
vs Semaglutide / Survodutide
Comparative GLP-1R+GCGR vs GLP-1R-only pharmacology; isolated GCGR hepatic mechanism vs tirzepatide/retatrutide
Quick Specs
| Form | Lyophilized powder |
| Purity | ≥99% by HPLC — every batch |
| CAS Number | 1884736-23-5 |
| Also Known As | MEDI0382, Cotadutide |
| Peptide Type | Dual GLP-1R/GCGR Co-Agonist (31 AA) |
| Molecular Weight | ~3,968 Da |
| Identity | MS molecular weight confirmed — every batch |
| COA | Janoshik-independent, publicly verifiable |
| Developer | AstraZeneca / MedImmune |
| Manufacture | In-house Fmoc SPPS — Qingdao, China |
| Storage | -20°C sealed | 2–8°C reconstituted (use within 28 days) |
| Shelf Life | 24 months unopened |
